Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 long-term safety and efficacy study of TAK-279 in moderate to severe plaque psoriasis
MOH_2024-11-06_013717Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zasocitinib in plaque psoriasis, sponsored by Takeda. Primary endpoints: Long-term safety, Long-term tolerability and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2024-11-06_013717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-06_013717.